Want to see IN:MEDICO full AI Analyst Report?
Top Page
Medico Remedies Ltd.
(MEDICO)
Select Model
Select Model
Rating:52Neutral
Price Target:
₹19.00
▼(-62.12% Downside)
Action:Reiterated
Date:09/29/26
The score is held back primarily by weak cash flow quality (volatile operating cash flow and negative FY2026 free cash flow) and a strongly bearish technical picture (price well below key moving averages with negative MACD and very low RSI/Stochastic). These are partially offset by solid revenue/earnings progress and a generally healthy balance sheet, with valuation appearing moderate based on the P/E provided.
Positive Factors
Revenue Growth
The return to approximately 20% revenue growth indicates strengthening commercial momentum and expanding business activity. If maintained, this larger revenue base can support operating leverage, improve reinvestment capacity, and provide a durable foundation for earnings growth over the coming quarters.
Negative Factors
Weak Cash Conversion
The sharp FY2026 decline in operating cash flow despite higher net income indicates weaker earnings-to-cash conversion and possible working-capital intensity. Negative free cash flow also suggests internal cash generation may not currently cover investment needs, increasing reliance on funding if the pattern persists.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The return to approximately 20% revenue growth indicates strengthening commercial momentum and expanding business activity. If maintained, this larger revenue base can support operating leverage, improve reinvestment capacity, and provide a durable foundation for earnings growth over the coming quarters.
Read all positive factors
Medico Remedies Ltd. (MEDICO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹1.55B
Dividend YieldN/A
Average Volume (3M)41.17K
Price to Earnings (P/E)11.1
Beta (1Y)0.35
Revenue Growth49.96%
EPS Growth33.70%
CountryIN
Employees105
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)1.67
Shares Outstanding82,984,000
10 Day Avg. Volume7,072
30 Day Avg. Volume41,175
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)3.60
Price to Sales (P/S)1.32
P/FCF Ratio-78.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medico Remedies Ltd. Business Overview & Revenue Model
Company Description
Medico Remedies Ltd. engages in the manufacture, supply, and exportation of pharmaceutical drugs. Its product portfolio includes general formulations, which consists of general tablets, capsules, and dry syrups; and beta lactum formulations, which...
Medico Remedies Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.38B | 2.06B | 1.51B | 1.45B | 1.40B | 1.21B |
| Gross Profit | 496.22M | 445.57M | 426.11M | 175.25M | 355.66M | 176.65M |
| EBITDA | 221.00M | 229.60M | 150.03M | 148.57M | 135.66M | 74.34M |
| Net Income | 138.15M | 131.15M | 100.93M | 82.91M | 72.42M | 48.12M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.53B | 1.20B | 961.95M | 874.48M | 774.04M |
| Cash, Cash Equivalents and Short-Term Investments | 37.51M | 37.51M | 25.45M | 15.46M | 21.95M | 23.40M |
| Total Debt | 0.00 | 192.04M | 147.00M | 80.50M | 97.62M | 125.97M |
| Total Liabilities | -754.75M | 779.29M | 573.30M | 438.24M | 436.05M | 408.30M |
| Stockholders Equity | 754.75M | 754.75M | 624.69M | 523.71M | 438.43M | 373.20M |
Cash Flow | ||||||
| Free Cash Flow | -5.86M | -34.84M | 17.07M | 2.04M | 15.75M | -11.50M |
| Operating Cash Flow | 6.43M | 10.06M | 48.92M | 24.38M | 81.67M | 58.62M |
| Investing Cash Flow | -12.01M | -46.47M | -34.60M | -26.77M | -66.03M | -17.56M |
| Financing Cash Flow | -2.70M | 44.53M | -5.20M | -4.90M | -18.17M | -57.71M |
Medico Remedies Ltd. Technical Analysis
Negative
50.16
Price Trends
30.38
Negative
36.38
Negative
40.10
Negative
Market Momentum
-3.03
Negative
18.17
Positive
6.34
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDICO, the sentiment is Negative. The current price of 50.16 is above the 20-day moving average (MA) of 21.21, above the 50-day MA of 30.38, and above the 200-day MA of 40.10, indicating a bearish trend. The MACD of -3.03 indicates Negative momentum. The RSI at 18.17 is Positive, neither overbought nor oversold. The STOCH value of 6.34 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDICO.
Medico Remedies Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | ₹3.47B | 31.99 | ― | 0.39% | 24.66% | 10.89% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹4.35B | 19.29 | ― | 0.65% | 11.43% | 258.53% | |
54 Neutral | ₹10.60B | 136.14 | ― | 1.93% | -3.14% | -5.80% | |
52 Neutral | ₹1.55B | 11.14 | ― | ― | 49.96% | 33.70% | |
50 Neutral | ₹6.95B | 43.53 | ― | ― | 89.64% | 10627.64% | |
50 Neutral | ₹7.32B | 166.21 | ― | 0.15% | 7.55% | -57.19% |
* General Sector Average
IN:MEDICO
Medico Remedies Ltd.
18.65
-31.85
-63.07%
IN:ALBERTDAVD
Albert David Ltd
762.90
-81.56
-9.66%
IN:BAFNAPH
Bafna Pharmaceuticals Limited
447.90
293.45
190.00%
IN:MEDICAMEQ
Medicamen Biotech Limited
255.50
-120.26
-32.01%
IN:VALIANTLAB
Valiant Laboratories Ltd.
127.90
44.90
54.10%
IN:ZIMLAB
Zim Laboratories Ltd.
136.45
62.99
85.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.